Atomo Secures $410,000 Order From Lumos to Support FebriDx Rollout in US; Shares Down 5%

MT Newswires Live

Aug 07, 2025

Atomo Diagnostics (ASX:AT1) said its strategic partner Lumos Diagnostics (ASX:LDX) placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.

The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.

The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.

Atomo Diagnostics' shares fell 5% in recent Thursday trade. Lumos Diagnostics' shares jumped almost 6%, earlier hitting their highest since September 2023.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2557538323"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557538323\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557538323?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557538323","market":"sh","top_or_hot":-1,"title":"Atomo Secures $410,000 Order From Lumos to Support FebriDx Rollout in US; Shares Down 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/AT1.AU\">Atomo Diagnostics</a> (ASX:AT1) said its strategic partner <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX)  placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.</p><p>The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.</p><p>The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.</p><p>Atomo Diagnostics' shares fell 5% in recent Thursday trade. <a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a>' shares jumped almost 6%, earlier hitting their highest since September 2023.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Atomo Secures $410,000 Order From Lumos to Support FebriDx Rollout in US; Shares Down 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAtomo Secures $410,000 Order From Lumos to Support FebriDx Rollout in US; Shares Down 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-07 12:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/AT1.AU\">Atomo Diagnostics</a> (ASX:AT1) said its strategic partner <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX)  placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.</p><p>The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.</p><p>The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.</p><p>Atomo Diagnostics' shares fell 5% in recent Thursday trade. <a href=\"https://laohu8.com/S/LDX.AU\">Lumos Diagnostics</a>' shares jumped almost 6%, earlier hitting their highest since September 2023.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557538323","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557538323","pubTimestamp":1754539860,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Atomo Diagnostics  said its strategic partner Lumos Diagnostics   placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments  waiver is granted and contracted minimum order quantities are achieved.The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.Atomo Diagnostics' shares fell 5% in recent Thursday trade. Lumos Diagnostics' shares jumped almost 6%, earlier hitting their highest since September 2023.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK7126":"医疗保健用品","BK7007":"医疗保健设备","AT1.AU":"ATOMO DIAGNOSTICS LTD","CLIA":"VERIDIEN CLIMATE ACTION ETF"},"translate_title":"Atomo从Lumos获得410,000美元的订单，以支持FebriDx在美国的推出；股价下跌5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLIA":1,"AT1.AU":0.9,"LDX.AU":0.9},"content_text":"Atomo Diagnostics (ASX:AT1) said its strategic partner Lumos Diagnostics (ASX:LDX)  placed an order with the company for the supply of $410,000 worth of Pascal cassettes to support scaling up the demand for the company's diagnostic product, FebriDx, in the US market, according to a Thursday Australian bourse filing.The company said that Lumos indicated that it expects the agreement with Phase to generate FebriDx product sales of up to $316 million over six years, assuming that the clinical laboratory improvement amendments (CLIA) waiver is granted and contracted minimum order quantities are achieved.The FebriDx test secured a 510k clearance from the US Food and Drug Administration and is currently well progressed through a CLIA waiver study that is expected to be completed this month.Atomo Diagnostics' shares fell 5% in recent Thursday trade. Lumos Diagnostics' shares jumped almost 6%, earlier hitting their highest since September 2023.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}